Mechanism of action
Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein located at the brush border of the small intestine. This transporter is responsible for the uptake of both dietary cholesterol and cholesterol re-secreted in bile.
By blocking NPC1L1, ezetimibe reduces intestinal cholesterol absorption by approximately 50%. This leads to decreased delivery of cholesterol to the liver, which triggers compensatory upregulation of hepatic LDL receptors and increased clearance of LDL cholesterol from the bloodstream.
Ezetimibe does not affect the absorption of fat-soluble vitamins, triglycerides, or bile acids. Its site of action is entirely intestinal and extrahepatic, making it mechanistically distinct from statins (which inhibit HMG-CoA reductase in the liver). When combined with a statin, ezetimibe provides additive LDL-lowering effects through complementary pathways: reduced hepatic synthesis plus reduced intestinal absorption.
Key mechanistic points
- Target: NPC1L1 transporter in intestinal enterocytes
- Result: 50% reduction in cholesterol absorption from gut
- Hepatic response: Upregulation of LDL receptors
- Net effect: Decreased plasma LDL cholesterol by 15-20% as monotherapy, additional 15-20% when added to statin
- Ezetimibe blocks NPC1L1 cholesterol transporter in the intestinal brush border, reducing cholesterol absorption by 50%
- Monotherapy reduces LDL by approximately 18%; adds 15-20% further reduction when combined with statins
- IMPROVE-IT trial showed cardiovascular benefit when ezetimibe added to simvastatin in post-ACS patients
- Does NOT affect absorption of fat-soluble vitamins A, D, E, or K
- Metabolized by glucuronidation, NOT cytochrome P450, resulting in fewer drug interactions
- Bile acid sequestrants reduce ezetimibe absorption; separate dosing by 2-4 hours
- Specifically indicated for homozygous sitosterolemia (phytosterolemia)
- When combined with statins, contraindicated in active liver disease and pregnancy
Indications
Ezetimibe is approved for the treatment of lipid disorders, typically as adjunct to diet modification.
Primary hyperlipidemia
Ezetimibe is used in patients with primary hypercholesterolemia (heterozygous familial and non-familial) either as monotherapy when statins are not tolerated or in combination with statins for additional LDL reduction.
Homozygous familial hypercholesterolemia
Used in combination with a statin in patients with homozygous familial hypercholesterolemia to reduce elevated total cholesterol and LDL cholesterol.
Mixed hyperlipidemia
Effective in patients with mixed hyperlipidemia to reduce elevated LDL cholesterol and non-HDL cholesterol.
Homozygous sitosterolemia (phytosterolemia)
Ezetimibe is specifically indicated for reducing sitosterol and campesterol levels in patients with this rare genetic disorder of sterol absorption.
Atherosclerotic cardiovascular disease prevention
While not a first-line agent, ezetimibe is used in combination with statins in patients with established ASCVD who require additional LDL lowering to reach target levels. The IMPROVE-IT trial demonstrated cardiovascular benefit when ezetimibe was added to simvastatin in post-ACS patients.
Pharmacokinetics
Absorption: Ezetimibe is rapidly absorbed following oral administration. It undergoes extensive first-pass glucuronidation in the intestinal wall to ezetimibe-glucuronide, which is pharmacologically active.
Distribution: Both ezetimibe and its glucuronide are highly protein-bound (greater than 90%). The drugs undergo enterohepatic recirculation, which contributes to their prolonged half-life and once-daily dosing.
Metabolism: Primarily metabolized via glucuronidation (a phase II reaction) in the small intestine and liver. Ezetimibe-glucuronide is the major active form found in plasma. There is minimal involvement of cytochrome P450 enzymes, which reduces the potential for drug-drug interactions compared to statins.
Excretion: Approximately 78% is excreted in feces (primarily as ezetimibe) and 11% in urine (primarily as glucuronide conjugate). The elimination half-life is approximately 22 hours for both ezetimibe and its active metabolite.
Special populations: No dose adjustment is needed in elderly patients or those with mild hepatic impairment. Ezetimibe is not recommended in patients with moderate to severe hepatic impairment. Renal impairment does not significantly affect pharmacokinetics.
Adverse effects
Ezetimibe is generally well tolerated, with an adverse effect profile similar to placebo when used as monotherapy. However, when combined with statins, the risk of certain adverse effects increases.
Common adverse effects
- Gastrointestinal: Diarrhea, abdominal pain
- Musculoskeletal: Myalgia, arthralgia, back pain
- Upper respiratory: Sinusitis, pharyngitis
- Fatigue: Generally mild
Serious adverse effects
Hepatotoxicity: Elevations in serum transaminases can occur, particularly when ezetimibe is combined with a statin. Liver function tests should be monitored according to statin labeling when used in combination. Ezetimibe is contraindicated in combination with a statin in patients with active liver disease.
Myopathy and rhabdomyolysis: While rare with ezetimibe monotherapy, the risk increases when combined with statins, particularly at higher statin doses or in the presence of other risk factors. Patients should be instructed to report unexplained muscle pain, tenderness, or weakness.
Hypersensitivity reactions: Rare cases of angioedema, rash, and urticaria have been reported. Anaphylaxis has been reported in postmarketing surveillance.
Pancreatitis: Rare cases have been reported in postmarketing experience.
Comparison with statin monotherapy
Ezetimibe monotherapy has a lower incidence of myalgia and hepatotoxicity compared to statins, making it an option for statin-intolerant patients.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to ezetimibe or any component of the formulation
- When used with a statin: Active hepatic disease or unexplained persistent elevations in serum transaminases
- When used with a statin: Pregnancy and breastfeeding (due to statin component)
Warnings and precautions
Hepatic impairment: Ezetimibe is not recommended in patients with moderate to severe hepatic impairment due to unknown effects of increased exposure. When used with a statin, liver function should be monitored according to statin recommendations.
Pregnancy and lactation: Ezetimibe alone is not expected to cause fetal harm based on animal data, but there are no adequate studies in pregnant women. When used in combination with a statin, the combination is contraindicated in pregnancy due to the statin component (statins are pregnancy category X). It is unknown whether ezetimibe is excreted in human milk.
Anticoagulation: In postmarketing reports, increased INR has been observed in patients receiving warfarin. INR should be appropriately monitored when ezetimibe is added to warfarin.
Skeletal muscle effects: Myopathy and rhabdomyolysis are increased when fibrates (especially gemfibrozil) are used with ezetimibe. Caution is advised, though fenofibrate may be used with closer monitoring.
Drug interactions
Ezetimibe has relatively few drug interactions due to its minimal metabolism via cytochrome P450 enzymes.
Fibrates
Gemfibrozil: Concurrent use increases ezetimibe concentrations and increases the risk of cholelithiasis and myopathy. Coadministration of ezetimibe with gemfibrozil is not recommended.
Fenofibrate: May also increase ezetimibe exposure but is considered safer than gemfibrozil. The combination can be used with monitoring, particularly in patients requiring aggressive lipid lowering.
Bile acid sequestrants
Cholestyramine, colestipol, colesevelam: These agents can decrease ezetimibe absorption. Ezetimibe should be administered either at least 2 hours before or at least 4 hours after bile acid sequestrant administration.
Cyclosporine
Cyclosporine increases ezetimibe exposure. In transplant patients receiving cyclosporine, ezetimibe concentrations should be monitored if clinically indicated, though routine dose adjustment is not typically necessary.
Warfarin
Postmarketing reports have noted increased INR in patients receiving warfarin and ezetimibe. Monitor INR when initiating or altering ezetimibe therapy in patients on warfarin.
Statins
No pharmacokinetic interaction occurs between ezetimibe and statins, which is why the combination is pharmacologically rational and widely used. The lipid-lowering effects are additive.
Clinical pearls
- Complementary to statins: Ezetimibe is the only oral agent that specifically targets intestinal cholesterol absorption. When added to a statin, it provides an additional 15-20% LDL reduction through a complementary mechanism.
- Statin intolerance: Ezetimibe monotherapy is a reasonable option for patients who cannot tolerate statins due to myalgias or other adverse effects, though the LDL reduction is more modest (approximately 18% as monotherapy).
- IMPROVE-IT trial: This landmark cardiovascular outcomes trial demonstrated that adding ezetimibe to simvastatin in post-acute coronary syndrome patients reduced major cardiovascular events, supporting the "lower is better" hypothesis for LDL cholesterol.
- No vitamin malabsorption: Unlike older agents that might interfere with lipid absorption, ezetimibe does not impair absorption of fat-soluble vitamins (A, D, E, K), making it safer for long-term use.
- Once-daily dosing: The long half-life (22 hours) allows convenient once-daily administration without regard to meals.
- Combination products: Ezetimibe is available in fixed-dose combinations with simvastatin and other statins, which may improve adherence in patients requiring both drugs.
- Sitosterolemia: Ezetimibe is uniquely effective in homozygous sitosterolemia, a rare condition where plant sterols accumulate. This is a specific board-testable indication.
- Minimal P450 interaction: Because ezetimibe is metabolized via glucuronidation rather than cytochrome P450 enzymes, it has fewer drug-drug interactions than many other lipid-lowering agents.
EZE the gut: Ezetimibe blocks cholesterol at the Enteric (intestinal) level via NPC1L1, while statins work in the liver
Practice questions
1. A 58-year-old man with a history of myocardial infarction 6 months ago presents for follow-up. Despite maximum-tolerated atorvastatin therapy, his LDL cholesterol remains at 110 mg/dL (target <70 mg/dL). His physician adds ezetimibe to his regimen. What is the primary mechanism by which ezetimibe will further reduce his LDL cholesterol?
2. A 45-year-old woman with heterozygous familial hypercholesterolemia is started on ezetimibe and simvastatin combination therapy. Four weeks later, she develops severe muscle pain and dark urine. Laboratory studies show creatine kinase 15,000 U/L (normal <200) and serum creatinine 2.1 mg/dL (baseline 0.9 mg/dL). Which property of ezetimibe made this adverse effect more likely when combined with simvastatin?
3. A 62-year-old man with hyperlipidemia has been taking ezetimibe for 3 months along with cholestyramine for additional LDL reduction. Despite good medication adherence, his lipid panel shows minimal improvement. His physician realizes the medications may be interacting. What is the most appropriate adjustment to optimize ezetimibe efficacy?
Frequently asked questions
How does ezetimibe work?
Ezetimibe works by blocking the NPC1L1 (Niemann-Pick C1-Like 1) protein transporter in the brush border of the small intestine. This prevents cholesterol absorption from the gut, reducing the amount of cholesterol delivered to the liver. In response, the liver upregulates LDL receptors, which increases clearance of LDL cholesterol from the blood. This mechanism is complementary to statins, which block cholesterol synthesis in the liver rather than absorption in the gut.
What are the side effects of ezetimibe?
Ezetimibe is generally well tolerated with side effects similar to placebo when used alone. The most common adverse effects include diarrhea, abdominal pain, myalgia, arthralgia, and upper respiratory symptoms like sinusitis. Serious but rare side effects include hepatotoxicity (liver enzyme elevations, especially when combined with statins), myopathy, rhabdomyolysis (particularly with statin combinations), and hypersensitivity reactions including angioedema. The risk of muscle-related side effects increases significantly when ezetimibe is combined with statins or fibrates.
Is ezetimibe a statin?
No, ezetimibe is not a statin. It belongs to a different drug class called cholesterol absorption inhibitors. Statins work by inhibiting HMG-CoA reductase in the liver to reduce cholesterol synthesis, while ezetimibe blocks the NPC1L1 transporter in the intestine to prevent cholesterol absorption. Because they work through different mechanisms, ezetimibe and statins are often used together to achieve greater LDL cholesterol reduction than either drug alone. Ezetimibe is commonly used in patients who cannot tolerate statins or need additional cholesterol lowering beyond what a statin provides.
Ezetimibe vs simvastatin — what is the difference?
Ezetimibe and simvastatin lower cholesterol through different mechanisms and at different sites. Ezetimibe blocks cholesterol absorption in the intestinal brush border by inhibiting the NPC1L1 transporter, while simvastatin inhibits HMG-CoA reductase in the liver to reduce cholesterol synthesis. Simvastatin typically provides greater LDL reduction (30-40%) compared to ezetimibe monotherapy (approximately 18%). However, ezetimibe has fewer side effects, particularly muscle-related symptoms. The two drugs are often combined for additive effects, and this combination was shown to reduce cardiovascular events in the IMPROVE-IT trial.
Can ezetimibe be taken with statins?
Yes, ezetimibe can and often should be taken with statins for additive cholesterol-lowering effects. The drugs work through complementary mechanisms—statins reduce cholesterol synthesis in the liver while ezetimibe blocks cholesterol absorption in the intestine. Together, they provide approximately 15-20% additional LDL reduction beyond statin monotherapy. The IMPROVE-IT trial demonstrated cardiovascular benefit from this combination. However, combining the drugs increases the risk of liver enzyme elevations and myopathy, so liver function should be monitored and patients should report any unexplained muscle symptoms. Fixed-dose combination products are available to improve adherence.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C10AX09
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.